Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Analysts at HC Wainwright upped their Q2 2025 earnings estimates for Alpha Tau Medical in a report issued on Tuesday, April 29th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). HC Wainwright has a "Buy" rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical's Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.47) EPS.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last posted its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13).
Alpha Tau Medical Price Performance
Shares of DRTS traded down $0.02 during mid-day trading on Thursday, hitting $2.60. The stock had a trading volume of 12,631 shares, compared to its average volume of 47,403. Alpha Tau Medical has a 52 week low of $1.75 and a 52 week high of $4.39. The business has a fifty day moving average price of $2.63 and a 200-day moving average price of $2.86. The firm has a market cap of $182.99 million, a P/E ratio of -6.05 and a beta of 0.93.
Institutional Investors Weigh In On Alpha Tau Medical
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Levin Capital Strategies L.P. lifted its stake in shares of Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock valued at $975,000 after buying an additional 7,189 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after buying an additional 26,800 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Alpha Tau Medical by 112.6% in the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after purchasing an additional 25,770 shares in the last quarter. 2.65% of the stock is currently owned by institutional investors.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Featured Stories
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
